CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
NASDAQ:CCRN - Nasdaq - US2274831047 - Common Stock - Currency: USD
CCRN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 109 industry peers in the Health Care Providers & Services industry. While CCRN has a great health rating, its profitability is only average at the moment. CCRN has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
In the past year CCRN had a positive cash flow from operations.
In multiple years CCRN reported negative net income over the last 5 years.
Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
CCRN has a Return On Assets of -0.30%. This is comparable to the rest of the industry: CCRN outperforms 54.63% of its industry peers.
The Return On Equity of CCRN (-0.42%) is comparable to the rest of the industry.
CCRN has a Return On Invested Capital (2.00%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CCRN is significantly above the industry average of 8.01%.
The last Return On Invested Capital (2.00%) for CCRN is well below the 3 year average (21.83%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.3% | ||
| ROE | -0.42% | ||
| ROIC | 2% |
ROA(3y)16.2%
ROA(5y)5.97%
ROE(3y)33.65%
ROE(5y)11.41%
ROIC(3y)21.83%
ROIC(5y)14.11%
1.3 Margins
With a Operating Margin value of 0.91%, CCRN perfoms like the industry average, outperforming 42.59% of the companies in the same industry.
In the last couple of years the Operating Margin of CCRN has grown nicely.
The Gross Margin of CCRN (20.91%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.91% | ||
| PM (TTM) | N/A | ||
| GM | 20.91% |
OM growth 3Y54.33%
OM growth 5Y25.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y-2.78%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CCRN is creating value.
The number of shares outstanding for CCRN has been reduced compared to 1 year ago.
Compared to 5 years ago, CCRN has less shares outstanding
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.54 indicates that CCRN is not in any danger for bankruptcy at the moment.
CCRN has a better Altman-Z score (5.54) than 87.96% of its industry peers.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.54 |
ROIC/WACC0.22
WACC8.93%
2.3 Liquidity
CCRN has a Current Ratio of 2.79. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
CCRN's Current ratio of 2.79 is amongst the best of the industry. CCRN outperforms 86.11% of its industry peers.
CCRN has a Quick Ratio of 2.79. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.79, CCRN belongs to the best of the industry, outperforming 87.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.79 |
3. Growth
3.1 Past
The earnings per share for CCRN have decreased strongly by -76.74% in the last year.
The Earnings Per Share has been growing by 76.23% on average over the past years. This is a very strong growth
CCRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.18%.
The Revenue has been growing by 19.86% on average over the past years. This is quite good.
EPS 1Y (TTM)-76.74%
EPS 3Y68.74%
EPS 5Y76.23%
EPS Q2Q%-69.23%
Revenue 1Y (TTM)-35.18%
Revenue growth 3Y34.16%
Revenue growth 5Y19.86%
Sales Q2Q%-28.75%
3.2 Future
The Earnings Per Share is expected to decrease by -32.13% on average over the next years. This is quite bad
The Revenue is expected to decrease by -13.67% on average over the next years. This is quite bad
EPS Next Y-75.41%
EPS Next 2Y-48.64%
EPS Next 3Y-32.13%
EPS Next 5YN/A
Revenue Next Year-33.32%
Revenue Next 2Y-21.04%
Revenue Next 3Y-13.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 26.05, the valuation of CCRN can be described as expensive.
64.81% of the companies in the same industry are more expensive than CCRN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CCRN to the average of the S&P500 Index (29.39), we can say CCRN is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 31.29, the valuation of CCRN can be described as expensive.
CCRN's Price/Forward Earnings ratio is in line with the industry average.
CCRN is valuated cheaply when we compare the Price/Forward Earnings ratio to 94.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.05 | ||
| Fwd PE | 31.29 |
4.2 Price Multiples
CCRN's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CCRN indicates a rather cheap valuation: CCRN is cheaper than 96.30% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.07 | ||
| EV/EBITDA | 17.01 |
4.3 Compensation for Growth
A cheap valuation may be justified as CCRN's earnings are expected to decrease with -32.13% in the coming years.
PEG (NY)N/A
PEG (5Y)0.34
EPS Next 2Y-48.64%
EPS Next 3Y-32.13%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CROSS COUNTRY HEALTHCARE INC
NASDAQ:CCRN (2/12/2025, 10:01:30 AM)
18.235
0 (-0.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners106.98%
Inst Owner Change-36.73%
Ins Owners5.59%
Ins Owner Change0%
Market Cap600.30M
Analysts52.31
Price Target17.81 (-2.33%)
Short Float %5.95%
Short Ratio2.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.89%
Min EPS beat(2)-26.01%
Max EPS beat(2)22.23%
EPS beat(4)3
Avg EPS beat(4)2.25%
Min EPS beat(4)-26.01%
Max EPS beat(4)22.23%
EPS beat(8)6
Avg EPS beat(8)5.46%
EPS beat(12)10
Avg EPS beat(12)7.75%
EPS beat(16)14
Avg EPS beat(16)22.92%
Revenue beat(2)0
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-0.29%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)0.37%
Revenue beat(8)3
Avg Revenue beat(8)0.3%
Revenue beat(12)6
Avg Revenue beat(12)0.74%
Revenue beat(16)10
Avg Revenue beat(16)3.26%
PT rev (1m)0%
PT rev (3m)-4.08%
EPS NQ rev (1m)0.62%
EPS NQ rev (3m)-4.57%
EPS NY rev (1m)0%
EPS NY rev (3m)2.72%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-2.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.05 | ||
| Fwd PE | 31.29 | ||
| P/S | 0.41 | ||
| P/FCF | 6.07 | ||
| P/OCF | 5.56 | ||
| P/B | 1.41 | ||
| P/tB | 2.47 | ||
| EV/EBITDA | 17.01 |
EPS(TTM)0.7
EY3.84%
EPS(NY)0.58
Fwd EY3.2%
FCF(TTM)3
FCFY16.48%
OCF(TTM)3.28
OCFY17.99%
SpS43.99
BVpS12.9
TBVpS7.38
PEG (NY)N/A
PEG (5Y)0.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.3% | ||
| ROE | -0.42% | ||
| ROCE | 2.77% | ||
| ROIC | 2% | ||
| ROICexc | 2.31% | ||
| ROICexgc | 4.13% | ||
| OM | 0.91% | ||
| PM (TTM) | N/A | ||
| GM | 20.91% | ||
| FCFM | 6.83% |
ROA(3y)16.2%
ROA(5y)5.97%
ROE(3y)33.65%
ROE(5y)11.41%
ROIC(3y)21.83%
ROIC(5y)14.11%
ROICexc(3y)22.07%
ROICexc(5y)14.26%
ROICexgc(3y)32.8%
ROICexgc(5y)21.74%
ROCE(3y)30.3%
ROCE(5y)19.59%
ROICexcg growth 3Y52.91%
ROICexcg growth 5Y28.64%
ROICexc growth 3Y65.44%
ROICexc growth 5Y37.16%
OM growth 3Y54.33%
OM growth 5Y25.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y-2.78%
F-Score5
Asset Turnover2.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.48% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 342.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.79 | ||
| Altman-Z | 5.54 |
F-Score5
WACC8.93%
ROIC/WACC0.22
Cap/Depr(3y)72.91%
Cap/Depr(5y)55.1%
Cap/Sales(3y)0.48%
Cap/Sales(5y)0.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.74%
EPS 3Y68.74%
EPS 5Y76.23%
EPS Q2Q%-69.23%
EPS Next Y-75.41%
EPS Next 2Y-48.64%
EPS Next 3Y-32.13%
EPS Next 5YN/A
Revenue 1Y (TTM)-35.18%
Revenue growth 3Y34.16%
Revenue growth 5Y19.86%
Sales Q2Q%-28.75%
Revenue Next Year-33.32%
Revenue Next 2Y-21.04%
Revenue Next 3Y-13.67%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y107.05%
EBIT growth 5Y50.25%
EBIT Next Year-55.63%
EBIT Next 3Y-21.19%
EBIT Next 5YN/A
FCF growth 1Y109.14%
FCF growth 3Y118.12%
FCF growth 5Y70.24%
OCF growth 1Y91.45%
OCF growth 3Y109.05%
OCF growth 5Y63.92%